

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

Connie Lee Batlevi,¹ Yvette Kasamon,² R. Gregory Bociek,³ Peter Lee,⁴ Lia Gore,⁵ Amanda Copeland,¹ Rachel Sorensen,⁶ Peter Ordentlich,⁶ Scott Cruickshank,⁶ Lori Kunkel,⁶ Daniela Buglio,⁷ Francisco Hernandez-Ilizaliturri,⁸ and Anas Younes^{4,7}

¹Memorial Sloan Kettering Cancer Center, New York, NY; ²John Hopkins University, Baltimore, MD; ³University of Nebraska Medical Center, Omaha, NE; ⁴Tower Cancer Research Foundation, Beverly Hills, CA; ⁵University of Colorado Cancer Center, Aurora, CO; ⁶Syndax Pharmaceuticals, Inc., Waltham, MA; ⁷MD Anderson Cancer Center, Houston, TX; and ⁸Roswell Park Cancer Institute, Buffalo, NY, USA

©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2016.142406

Received: January 13, 2016.

Accepted: April 29, 2016.

Pre-published: May 5, 2016.



Correspondence: younesa@mskcc.org

SUPPLEMENTAL DATA

Supplemental Figure 1. Kaplan-Meier estimates of overall survival and waterfall plot of evaluable patients (per protocol population) who previously underwent an autologous stem cell transplant (ASCT) (N=26). **A.** Kaplan-Meier estimates of OS measured from date of ASCT. **B.** Maximum decrease in tumor burden from baseline in patients with prior ASCT

Supplemental Figure 2. Entinostat therapy reduces TARC levels. Patients were assessed for TARC levels on day 1, 8 and 15 in cycle 1 of entinostat therapy. TARC levels were assessed in 20 patients with paired day 1 and day 8 TARC levels and 18 patients with paired day 1 and day 15 TARC levels. The changes in TARC levels between day 1 and day 8, as well as day 1 and day 15 were statistically significant as calculated by the Wilcoxon signed ranked test, $p < 0.0001$.

Supplemental Figure 1.



Supplemental Figure 2. Entinostat therapy reduces TARC Levels

